Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event.

HOME
>
論文・技術情報
>
Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event.

Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event.

アブストラクト	Isolated cases of acute coronary syndrome (ACS) associated with immune checkpoint inhibitors (ICIs) have been described without the establishment of a formal cause-and-effect relationship between treatment and adverse event. We reported a case of ACS after the first administration of an ICI and with a fatal recurrence in another coronary area immediately after readministration. According to guidelines, causality was considered to be certain. Subsequently, we queried the French pharmacovigilance database and found 4 cases of ACS with coronary artery thrombosis. Causality was probable in those patients. These data suggest that ACS may be another life-threatening cardiac adverse event occurring with ICI exposure.
ジャーナル名	The Canadian journal of cardiology
Pubmed追加日	2020/3/8
投稿者	Cautela, Jennifer; Rouby, Franck; Salem, Joe-Elie; Alexandre, Joachim; Scemama, Ugo; Dolladille, Charles; Cohen, Ariel; Paganelli, Franck; Ederhy, Stephane; Thuny, Franck
組織名	University Mediterranean Centre of Cardio-Oncology, Assistance Publique-Hopitaux;de Marseille, Aix-Marseille University, and Unit of Heart Failure and Valvular;Heart Diseases, Department of Cardiology, Hopital Nord, Marseille, France; Groupe;Mediterraneen de Cardio-Oncologie, Marseille, France; Centre for Cardiovascular;and Nutrition Research, Aix-Marseille University, INSERM 1263, INRA 1260,;Marseille, France.;Department of Clinical Pharmacology and Pharmacovigilance, Regional;Pharmacovigilance Centre of Marseille Provence Corse, Marseille, France.;UNICO-GRECO Cardio-Oncology Program, Sorbonne Universite, INSERM, CIC Paris-Est,;AP-HP, and Department of Pharmacology, Pitie-Salpetriere Hospital, Paris, France.;PICARO Cardio-Oncology Program, Department of Pharmacology, CHU de Caen, Caen,;France; Department of Cardiology, CHU de Caen, Caen, France; Signalisation,;Electrophysiologie et Imagerie des Lesions d'Ischemie-Reperfusion Myocardique,;Medical School, Universite de Caen Normandie, EA 4650, Caen, France.;Department of Imaging, Hopital Nord, Assistance Publique-Hopitaux de Marseille,;Aix-Marseille University, Marseille, France.;Sorbonne Universite, Hopitaux Universitaires Est Parisien, Hopital Saint Antoine,;and Hopital Tenon, Assistance Publique-Hopitaux de Paris, INSERM 856, Paris,;France.;Heart Diseases, Department of Cardiology, Hopital Nord, Marseille, France; Centre;for Cardiovascular and Nutrition Research, Aix-Marseille University, INSERM 1263,;INRA 1260, Marseille, France.;Marseille, France. Electronic address: franck.thuny@gmail.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/32144037/